Early start to certolizumab good for Crohn's patients

04/3/2010 | Medscape (free registration)

Starting Crohn's disease patients on certolizumab pegol shortly after diagnosis leads to particularly good results, according to a study in the American Journal of Gastroenterology. The researchers said additional study is needed but that the benefit-risk ratio "may well be acceptable" for using tumor necrosis factor-alpha blocking agents in early disease.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC